These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 16163196)
1. Mechanisms and treatment for bone metastases. Clines GA; Guise TA Clin Adv Hematol Oncol; 2004 May; 2(5):295-302. PubMed ID: 16163196 [TBL] [Abstract][Full Text] [Related]
2. Hypercalcaemia of malignancy and basic research on mechanisms responsible for osteolytic and osteoblastic metastasis to bone. Clines GA; Guise TA Endocr Relat Cancer; 2005 Sep; 12(3):549-83. PubMed ID: 16172192 [TBL] [Abstract][Full Text] [Related]
3. Molecular mechanisms and treatment of bone metastasis. Clines GA; Guise TA Expert Rev Mol Med; 2008 Mar; 10():e7. PubMed ID: 18321396 [TBL] [Abstract][Full Text] [Related]
4. The bisphosphonate olpadronate inhibits skeletal prostate cancer progression in a green fluorescent protein nude mouse model. Yang M; Burton DW; Geller J; Hillegonds DJ; Hastings RH; Deftos LJ; Hoffman RM Clin Cancer Res; 2006 Apr; 12(8):2602-6. PubMed ID: 16638872 [TBL] [Abstract][Full Text] [Related]
5. Hypercalcemia and bone resorption in malignancy. Walls J; Bundred N; Howell A Clin Orthop Relat Res; 1995 Mar; (312):51-63. PubMed ID: 7634618 [TBL] [Abstract][Full Text] [Related]
6. [PTHrP and breast cancer]. Devys A; Lortholary A; Audran M Bull Cancer; 2001 Nov; 88(11):1075-80. PubMed ID: 11741801 [TBL] [Abstract][Full Text] [Related]
7. Pathophysiology of bone metastases: how this knowledge may lead to therapeutic intervention. Lipton A J Support Oncol; 2004; 2(3):205-13; discussion 213-4, 216-7, 219-20. PubMed ID: 15328823 [TBL] [Abstract][Full Text] [Related]
8. The potential role of bisphosphonates in prostate cancer. Oades GM; Coxon J; Colston KW Prostate Cancer Prostatic Dis; 2002; 5(4):264-72. PubMed ID: 12627210 [TBL] [Abstract][Full Text] [Related]
9. Lowering bone mineral affinity of bisphosphonates as a therapeutic strategy to optimize skeletal tumor growth inhibition in vivo. Fournier PG; Daubiné F; Lundy MW; Rogers MJ; Ebetino FH; Clézardin P Cancer Res; 2008 Nov; 68(21):8945-53. PubMed ID: 18974139 [TBL] [Abstract][Full Text] [Related]
10. Malignancy and the skeleton. Mundy GR Horm Metab Res; 1997 Mar; 29(3):120-7. PubMed ID: 9137982 [TBL] [Abstract][Full Text] [Related]
11. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and the development of osteolytic metastases. de Vernejoul MC Rev Rhum Engl Ed; 1997 Jun; 64(6 Suppl):119S-123S. PubMed ID: 9273953 [No Abstract] [Full Text] [Related]
12. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921 [TBL] [Abstract][Full Text] [Related]
13. Targeting of therapeutic agents to bone to treat metastatic cancer. Bagi CM Adv Drug Deliv Rev; 2005 May; 57(7):995-1010. PubMed ID: 15876400 [TBL] [Abstract][Full Text] [Related]
14. Future treatment of bone metastases. Lipton A Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6305s-6308s. PubMed ID: 17062719 [TBL] [Abstract][Full Text] [Related]
15. Local effects of malignancy on bone. Brown SA; Clines GA; Guise TA Curr Opin Endocrinol Diabetes Obes; 2007 Dec; 14(6):436-41. PubMed ID: 17982348 [TBL] [Abstract][Full Text] [Related]
16. [Current use of bisphosphonates in clinical oncology]. Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372 [TBL] [Abstract][Full Text] [Related]
17. Targeting factors involved in bone remodeling as treatment strategies in prostate cancer bone metastasis. Vessella RL; Corey E Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6285s-6290s. PubMed ID: 17062715 [TBL] [Abstract][Full Text] [Related]
18. Hypercalcemia of malignancy: pathophysiology and implications for treatment. Theriault RL Oncology (Williston Park); 1993 Jan; 7(1):47-50; discussion 52-5. PubMed ID: 8420542 [TBL] [Abstract][Full Text] [Related]